United Therapeutics Corp Files 8-K

Ticker: UTHR · Form: 8-K · Filed: Aug 1, 2025

Sentiment: neutral

Topics: material-definitive-agreement, corporate-disclosure

Related Tickers: UNTH

TL;DR

UNTH filed an 8-K on Aug 1, 2025, likely a material agreement.

AI Summary

On August 1, 2025, United Therapeutics Corporation entered into a material definitive agreement. The filing also includes information regarding Regulation FD disclosure and financial statements and exhibits. The company is incorporated in Delaware and headquartered in Silver Spring, Maryland.

Why It Matters

This 8-K filing indicates a significant corporate event or agreement for United Therapeutics Corporation, requiring disclosure to the public.

Risk Assessment

Risk Level: low — This is a standard 8-K filing reporting a material definitive agreement, which is routine corporate disclosure.

Key Numbers

Key Players & Entities

FAQ

What type of material definitive agreement did United Therapeutics Corporation enter into?

The filing does not specify the exact nature of the material definitive agreement, only that one was entered into on August 1, 2025.

What is the primary business of United Therapeutics Corporation?

United Therapeutics Corporation is in the Pharmaceutical Preparations industry, SIC code 2834.

When is United Therapeutics Corporation's fiscal year end?

The company's fiscal year ends on December 31.

What is the address of United Therapeutics Corporation's principal executive offices?

The principal executive offices are located at 1000 Spring Street, Silver Spring, MD 20910.

What other items are included in this 8-K filing besides the material definitive agreement?

This 8-K filing also includes information on Regulation FD Disclosure and Financial Statements and Exhibits.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on August 1, 2025 regarding UNITED THERAPEUTICS Corp (UTHR).

View full filing on EDGAR

View on Read The Filing